Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



Theranexus announces the first European approval for its phase 2 clinical trial with THN 102 in Parkinson's disease patients
19/04/2018
Télécharger le PDF (278 Ko)

Theranexus announces a successful clinical pharmacokinetic study as part of the development of its drug candidates THN201 and THN101
21/03/2018
Download PDF File (309 Ko)

Theranexus and the Collège de France sign a research agreement on Astrocyte-Neuron interactions
15/03/2018
Download PDF File (187 Ko)

Theranexus announces issuance of European patent covering its drug candidate thn102 for treatment of narcolepsy and Parkinson's disease>
11/01/2018
Télécharger le PDF (801 Ko)

Success of Theranexus' IPO on Euronext Growth in Paris
25/10/2017
Download PDF File (917 Ko)

Du 4 au 7 juin 2018 : Bio International Convention, Boston

21 juin 2018 : Kepler Biotech Days, Paris

27 & 28 juin 2018 : European MidCap Event, Paris

5 septembre 2018: Conférence Biotechs Portzamparc, Paris

8 & 9 octobre 2018 : Large & MidCap Event, Paris

4 & 5 décembre 2018 : European MidCap Event, Genève